Progenics Pharmaceuticals, Inc. Aktie

Aktier

2024-03-01	Perspective Therapeutics, Inc. (NYSEAM:CATX) har slutfört förvärvet av produktionsanläggningen för radiofarmaka i Somerset, New Jersey från Progenics Pharmaceuticals, Inc.	CI
2020-05-07	Progenics Pharmaceuticals, Inc., Q1 2020 Earnings Call, May 07, 2020
2019-12-23	Progenics Pharmaceuticals, Inc. - Special Call
2019-10-02	Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc. - M&A Call
2019-08-09	Progenics Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 09, 2019
2019-05-09	Progenics Pharmaceuticals, Inc., Q1 2019 Earnings Call, May 09, 2019
2019-03-14	Progenics Pharmaceuticals, Inc., Q4 2018 Earnings Call, Mar 14, 2019
2018-11-13	Progenics Pharmaceuticals, Inc. Presents at 27th Annual Credit Suisse Healthcare Conference, Nov-13-2018 09:10 AM
2018-11-08	Progenics Pharmaceuticals, Inc., Q3 2018 Earnings Call, Nov 08, 2018
2018-10-05	Progenics Pharmaceuticals, Inc. - Special Call
2018-07-31	Progenics Pharmaceuticals, Inc. - Special Call
2018-05-09	Progenics Pharmaceuticals, Inc., Q1 2018 Earnings Call, May 09, 2018
2018-03-08	Progenics Pharmaceuticals, Inc., Q4 2017 Earnings Call, Mar 08, 2018

2024-03-01	Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.
2024-01-09	Perspective Therapeutics, Inc. entered into an asset purchase agreement to acquire Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc. for $8 million.
2020-12-28	International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc
2020-11-13	Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., and Exini Diagnostics AB Announces U.S. Food and Drug Administration Clearance for Ai-Enabled Automated Bone Scan Index in Prostate Cancer on GE Healthcare’S Xeleris Platform
2020-06-22	PROGENICS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)

Verkställande direktör	Titel	Ålder	Sedan
David Mims CEO	Verkställande Direktör	62	-

Datum	Insider	Typ	Huvudposition	Kvantitet	% av börsvärdet.
2020-06-19	David Mims	Försäljning av emittenten	Verkställande direktör	56 393	0,0651%
2020-06-19	Ann MacDougall	Försäljning av emittenten	Ordförande	76 065	0,0878%
2020-06-19	Heinz Christoph Mäusli	Försäljning av emittenten	Styrelseledamot	56 393	0,0651%

Lägg till i en lista 0 vald För att använda denna funktion måste du vara en kund eller medlem Logga in Registrera dig	Förändring	Varia. 5d.	Varia. 1 år	Föränd. 3 år	Kapi.($)
PROGENICS PHARMACEUTICALS, INC.	-.--%	+1,49 %	-	-	355 mn
ARGENX SE	+1,03 %	+2,30 %	+54,92 %	+111,78 %	55,58 md
WUXI APPTEC CO., LTD.	+2,72 %	+3,06 %	+53,28 %	+47,85 %	43,47 md
BIONTECH SE	+1,07 %	+2,84 %	−13,66 %	−17,49 %	22,64 md
INSMED INCORPORATED	+1,43 %	+3,45 %	+0,61 %	+399,85 %	20,96 md
WUXI BIOLOGICS (CAYMAN) INC.	+3,81 %	−4,13 %	+16,62 %	−30,70 %	15,79 md
GENMAB A/S	+0,15 %	+0,50 %	+9,10 %	−40,04 %	15,3 md
EXELIXIS, INC.	−0,56 %	+0,80 %	+27,14 %	+178,26 %	13,45 md
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5,27 %	+6,41 %	+21,05 %	-	11,74 md
PHARMAESSENTIA CORPORATION	+1,61 %	+1,17 %	+90,79 %	+212,97 %	10,96 md
Genomsnitt	+1,61 %	+0,26 %	+28,87 %	+107,81 %	23,32 md
Viktad genomsnitt av Capi.	+1,69 %	+1,60 %	+33,74 %	+100,50 %